Blog
RSS FeedPosted by Michael Wonder on 04 Apr 2024
New model validation tool to support economic evaluations of health technologies
1 April 2024 - CADTH has developed a comprehensive and accessible tool to support the validation of economic models used in ...
Posted by Michael Wonder on 02 Apr 2024
Mirum Pharmaceuticals’ Livmarli (maralixibat oral solution) receives positive reimbursement recommendation by Canada’s CADTH for patients with cholestatic pruritus in Alagille syndrome
2 April 2024 - Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with ...
Posted by Michael Wonder on 04 Mar 2024
Findings from the Lean review of our drug reimbursement review program
29 February 2024 - Last year, CADTH communicated several improvements to our drug reimbursement review program, including a Lean review ...
Posted by Michael Wonder on 19 Dec 2023
The Government of Canada announces the creation of the Canadian Drug Agency
18 December 2023 - Helping make Canada's drug system more sustainable and better prepared for the future. ...
Posted by Michael Wonder on 02 Nov 2023
Rhythm Pharmaceuticals receives positive CADTH reimbursement recommendation for Imcivree (setmelanotide)
2 November 2023 - Recommendation based on demonstrated clinical benefit in Phase 3 trial. ...
Posted by Michael Wonder on 13 Sep 2023
Paladin Labs announced favourable CADTH recommendation for Xcopri (cenobamate tablets)
12 September 2023 - Paladin Labs announced today that CADTH has recommended that Xcopri (cenobamate) be publicly reimbursed as adjunctive therapy ...
Posted by Michael Wonder on 28 Aug 2023
CADTH to establish industry task force on real world data for post market drug evaluations
18 August 2023 - CADTH is establishing an industry task force that will build upon the recently released guidance for reporting ...
Posted by Michael Wonder on 20 Jul 2023
Changes to CADTH’s rapid response service
20 July 2023 - As CADTH continues along the path of strategic transformation, we’re working hard to align the evidence products ...
Posted by Michael Wonder on 05 Jun 2023
Upcoming improvements to the CADTH reimbursement review process
5 June 2023 - Today, CADTH is communicating a series of improvements that will further our ambition to innovate in ...
Posted by Michael Wonder on 05 Jun 2023
Guidance for reporting real world evidence
31 May 2023 - CADTH has partnered with Health Canada, the Institut national d’excellence en santé et en services sociaux (INESSS), ...
Posted by Michael Wonder on 18 May 2023
Collaboration creates roadmap in Canada to report real world evidence studies
16 May 2023 - CADTH, Health Canada, and the Institut national d’excellence en santé et en services sociaux (INESSS) are ...
Posted by Michael Wonder on 27 Apr 2023
CADTH, ICER, and NICE release joint position statement on redacting clinical data awaiting publication
24 April 2023 - The position statement is a step toward greater transparency of unpublished data and a tangible outcome ...
Posted by Michael Wonder on 27 Apr 2023
CADTH formalises offering on real-world evidence through its scientific advice program
25 April 2023 - During a 1-year learning period, CADTH expanded its Scientific Advice program to include advice on real-world evidence ...
Posted by Michael Wonder on 09 Mar 2023
CADTH recommends reimbursement for BioCryst’s Orladeyo (berotralstat) for the routine prevention of attacks in hereditary angioedema patients in Canada
8 March 2023 - BioCryst Pharmaceuticals today announced that the CADTH Canadian Drug Expert Committee has issued a positive recommendation ...
Posted by Michael Wonder on 19 Jan 2023
Radicava (edarvarone) oral suspension receives positive recommendation from CADTH for the treatment of patients with ALS
18 January 2023 - Mitsubishi Tanabe Pharma Canada is pleased to announce a positive recommendation from the CADTH Canadian Drug Expert ...